ArticleNature communications2018
Germline variation at 8q24 and prostate cancer risk in men of European ancestry.
Erratum issued Registry-linked trialOpen access · goldAbstract read
In one paragraph
Article in Nature communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT01221168 (ProGene), which is not on this map. Cited by 43 papers.
0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
6.3field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
ProGene: Etude Genetique et Epidemiologique du Cancer de la Prostate Familial
Who cites it
43 citing papers in PubMed, 59 citations in OpenAlex.
- Cost-Effectiveness Analysis of Prostate Cancer Screening in the UK: A Decision Model Analysis Based on the CAP Trial.PharmacoEconomics · 2022Trial
- The effect of assessing genetic risk of prostate cancer on the use of PSA tests in primary care: A cluster randomized controlled trial.PLoS medicine · 2020Trial
- Distributed Pharmacodynamic Architecture in Multi-Component Herbal Formulations: A Flux-Based Framework for Redox-Heterogeneous Diseases.Pharmaceutics · 2026Review
- Polygenic risk and germline genetics for prostate cancer in Asians: Where do we stand?Investigative and clinical urology · 2026Review
- Review
- A New Era of Data-Driven Cancer Research and Care: Opportunities and Challenges.Cancer discovery · 2024Article
- Exploring Molecular Drivers of PARPi Resistance in BRCA1-Deficient Ovarian Cancer: The Role of LY6E and Immunomodulation.International journal of molecular sciences · 2024Article
- Article
- Integrated analyses highlight interactions between the three-dimensional genome and DNA, RNA and epigenomic alterations in metastatic prostate cancer.Nature genetics · 2024Article
- A west African ancestry-associated SNP on 8q24 predicts a positive biopsy in African American men with suspected prostate cancer following PSA screening.The Prostate · 2024Article
- Review
- Sex steroid hormone residues in milk and their potential risks for breast and prostate cancer.Frontiers in nutrition · 2024Review
- Analysis of genetic biomarkers, polymorphisms in ADME-related genes and their impact on pharmacotherapy for prostate cancer.Cancer cell international · 2023Review
- CanRisk-Prostate: A Comprehensive, Externally Validated Risk Model for the Prediction of Future Prostate Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Article
- Genetic risk factors have a substantial impact on healthy life years.Nature medicine · 2022Article
- MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets.Nature communications · 2022Article
- The BARCODE1 Pilot: a feasibility study of using germline single nucleotide polymorphisms to target prostate cancer screening.BJU international · 2022Article
- H3K27ac HiChIP in prostate cell lines identifies risk genes for prostate cancer susceptibility.American journal of human genetics · 2021Article
- Long non-coding RNAs and their potential impact on diagnosis, prognosis, and therapy in prostate cancer: racial, ethnic, and geographical considerations.Expert review of molecular diagnostics · 2021Review
- Article
Corrections and comments
- Erratum issued
Authors and funding
78 authors at 20 institutions in 21 countries.
Marco MatejcicDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA, 90033, USA.
Edward J SaundersThe Institute of Cancer Research, London, SW7 3RP, UK.
Tokhir DadaevThe Institute of Cancer Research, London, SW7 3RP, UK.ORCID http://orcid.org/0000-0002-8268-0438
Mark N BrookThe Institute of Cancer Research, London, SW7 3RP, UK.ORCID http://orcid.org/0000-0002-8969-2378
Kan WangDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA, 90033, USA.ORCID http://orcid.org/0000-0002-0640-6058
Xin ShengDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA, 90033, USA.
Ali Amin Al OlamaCentre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Strangeways Research Laboratory, University of Cambridge, Cambridge, CB1 8RN, UK.ORCID http://orcid.org/0000-0002-7178-3431
Fredrick R SchumacherDepartment of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH, 44106-7219, USA.ORCID http://orcid.org/0000-0002-3073-7463
Sue A InglesDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA, 90033, USA.
Koveela GovindasamiThe Institute of Cancer Research, London, SW7 3RP, UK.
Sara BenllochThe Institute of Cancer Research, London, SW7 3RP, UK.
Sonja I BerndtDivision of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, 20892, USA.
Demetrius AlbanesDivision of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, 20892, USA.
Stella KoutrosDivision of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, 20892, USA.
Kenneth MuirInstitute of Population Health, University of Manchester, Manchester, M13 9PL, UK.ORCID http://orcid.org/0000-0001-6429-988X
Victoria L StevensEpidemiology Research Program, American Cancer Society, 250 Williams Street, Atlanta, GA, 30303, USA.
Susan M GapsturEpidemiology Research Program, American Cancer Society, 250 Williams Street, Atlanta, GA, 30303, USA.
Catherine M TangenSWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109, USA.
Jyotsna BatraAustralian Prostate Cancer Research Centre-Qld, Institute of Health and Biomedical Innovation and School of Biomedical Science, Queensland University of Technology, Brisbane, QLD, 4059, Australia.ORCID http://orcid.org/0000-0003-4646-6247
Judith ClementsAustralian Prostate Cancer Research Centre-Qld, Institute of Health and Biomedical Innovation and School of Biomedical Science, Queensland University of Technology, Brisbane, QLD, 4059, Australia.
Henrik GronbergDepartment of Medical Epidemiology and Biostatistics, Karolinska Institute, SE-171 77, Stockholm, Sweden.
Nora PashayanCentre for Cancer Genetic Epidemiology, Department of Oncology, Strangeways Research Laboratory, University of Cambridge, Cambridge, CB1 8RN, UK.ORCID http://orcid.org/0000-0003-0843-2468
Johanna SchleutkerDepartment of Medical Biochemistry and Genetics, Institute of Biomedicine, University of Turku, FI-20014, Turku, Finland.ORCID http://orcid.org/0000-0002-1863-0305
Alicja WolkDivision of Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, SE-171 77, Stockholm, Sweden.ORCID http://orcid.org/0000-0001-7387-6845
Catharine WestDivision of Cancer Sciences, Manchester Academic Health Science Centre, Radiotherapy Related Research, Manchester NIHR Biomedical Research Centre, The Christie Hospital NHS Foundation Trust, University of Manchester, Manchester, M13 9PL, UK.
Lorelei MucciDepartment of Epidemiology, Harvard School of Public Health, Boston, MA, 02115, USA.
Peter KraftProgram in Genetic Epidemiology and Statistical Genetics, Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, 02115, USA.
Géraldine Cancel-TassinGRC N°5 ONCOTYPE-URO, UPMC Univ Paris 06, Tenon Hospital, F-75020, Paris, France.ORCID http://orcid.org/0000-0002-9583-6382
Karina D SorensenDepartment of Molecular Medicine, Aarhus University Hospital, 8200, Aarhus N, Denmark.ORCID http://orcid.org/0000-0002-4902-5490
Lovise MaehleDepartment of Medical Genetics, Oslo University Hospital, 0424, Oslo, Norway.
Eli M GrindedalDepartment of Medical Genetics, Oslo University Hospital, 0424, Oslo, Norway.
Sara S StromDepartment of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
David E NealDepartment of Oncology, Addenbrooke's Hospital, University of Cambridge, Cambridge, CB2 0QQ, UK.
Freddie C HamdyNuffield Department of Surgical Sciences, University of Oxford, Oxford, OX1 2JD, UK.
Jenny L DonovanSchool of Social and Community Medicine, University of Bristol, Canynge Hall, 39 Whatley Road, Bristol, BS8 2PS, UK.
Ruth C TravisCancer Epidemiology, Nuffield Department of Population Health, University of Oxford, Oxford, OX3 7LF, UK.
Robert J HamiltonDepartment of Surgical Oncology, Princess Margaret Cancer Centre, Toronto, ON, M5G 2M9, Canada.
Barry RosensteinDepartment of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
Yong-Jie LuCentre for Molecular Oncology, John Vane Science Centre, Barts Cancer Institute, Queen Mary University of London, London, EC1M 6BQ, UK.
Graham G GilesCancer Epidemiology & Intelligence Division, Cancer Council Victoria, Melbourne, VIC, 3004, Australia.
Adam S KibelDivision of Urologic Surgery, Brigham and Womens Hospital, Boston, MA, 02115, USA.
Ana VegaFundación Pública Galega de Medicina Xenómica-SERGAS, Grupo de Medicina Xenómica, CIBERER, IDIS, 15706, Santiago de Compostela, Spain.
Jeanette T BensenDepartment of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Columbia, SC, 29208, USA.
Manolis KogevinasCentre for Research in Environmental Epidemiology (CREAL), Barcelona Institute for Global Health (ISGlobal), 08003, Barcelona, Spain.
Kathryn L PenneyChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital/Harvard Medical School, Boston, MA, 02184, USA.
Jong Y ParkDepartment of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, 33612, USA.
Janet L StanfordDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109-1024, USA.
Cezary CybulskiInternational Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, 70-115, Szczecin, Poland.
Børge G NordestgaardFaculty of Health and Medical Sciences, University of Copenhagen, 2200, Copenhagen, Denmark.
Hermann BrennerDivision of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), D-69120, Heidelberg, Germany.
Christiane MaierInstitute for Human Genetics, University Hospital Ulm, 89075, Ulm, Germany.
Jeri KimDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Manuel R TeixeiraDepartment of Genetics, Portuguese Oncology Institute of Porto, 4200-072, Porto, Portugal.
Susan L NeuhausenDepartment of Population Sciences, Beckman Research Institute of the City of Hope, Duarte, CA, 91010, USA.
Kim De RuyckGhent University, Faculty of Medicine and Health Sciences, Basic Medical Sciences, B-9000, Gent, Belgium.
Azad RazackDepartment of Surgery, Faculty of Medicine, University of Malaya, 50603, Kuala Lumpur, Malaysia.
Lisa F NewcombDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109-1024, USA.
Davor LesselInstitute of Human Genetics, University Medical Center Hamburg-Eppendorf, D-20246, Hamburg, Germany.ORCID http://orcid.org/0000-0003-4496-244X
Radka KanevaMolecular Medicine Center, Department of Medical Chemistry and Biochemistry, Medical University of Sofia, 1431, Sofia, Bulgaria.
Nawaid UsmaniDepartment of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, T6G 1Z2, Canada.
Frank ClaessensMolecular Endocrinology Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, BE-3000, Leuven, Belgium.
Paul A TownsendManchester Cancer Research Centre, Faculty of Biology Medicine and Health, Manchester Academic Health Science Centre, NIHR Manchester Biomedical Research Centre, Health Innovation Manchester, University of Manchester, Manchester, M13 9WL, UK.
Manuela Gago-DominguezGenomic Medicine Group, Galician Foundation of Genomic Medicine, Instituto de Investigacion Sanitaria de Santiago de Compostela (IDIS), Complejo Hospitalario Universitario de Santiago, Servicio Galego de Saúde, SERGAS, 15706, Santiago de Compostela, Spain.
Monique J RoobolDepartment of Urology, Erasmus University Medical Center, 3015 CE, Rotterdam, The Netherlands.ORCID http://orcid.org/0000-0001-6967-1708
Florence MenegauxCancer and Environment Group, Center for Research in Epidemiology and Population Health (CESP), INSERM, University Paris-Sud, University Paris-Saclay, 94807, Villejuif Cédex, France.
Kay-Tee KhawClinical Gerontology Unit, University of Cambridge, Cambridge, CB2 2QQ, UK.
Lisa A Cannon-AlbrightDivision of Genetic Epidemiology, Department of Medicine, University of Utah School of Medicine, Salt Lake City, UT, 84112, USA.
Hardev PandhaThe University of Surrey, Guildford, Surrey, GU2 7XH, UK.
Stephen N ThibodeauDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, 55905, USA.
Daniel J SchaidDivision of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, 55905, USA.
PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium
Fredrik WiklundDepartment of Medical Epidemiology and Biostatistics, Karolinska Institute, SE-171 77, Stockholm, Sweden.
Stephen J ChanockDivision of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, 20892, USA.ORCID http://orcid.org/0000-0002-2324-3393
Douglas F EastonCentre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Strangeways Research Laboratory, University of Cambridge, Cambridge, CB1 8RN, UK.ORCID http://orcid.org/0000-0003-2444-3247
Rosalind A EelesThe Institute of Cancer Research, London, SW7 3RP, UK.ORCID http://orcid.org/0000-0002-3698-6241
Zsofia Kote-JaraiThe Institute of Cancer Research, London, SW7 3RP, UK.
David V ContiDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA, 90033, USA.
Christopher A HaimanDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA, 90033, USA. Christopher.Haiman@med.usc.edu.
Institute of Cancer Research · GBUniversity of Cambridge · GBKarolinska Institutet · SENational Cancer Institute · USUniversity of Southern California · USTranslational Research Institute · AUUniversity of Surrey · GBHarvard University · USMedical University of Sofia · BGMoffitt Cancer Center · USPrincess Margaret Cancer Centre · CASecond Military Medical University · CNComplejo Hospitalario Universitario de Santiago · ESErasmus MC · NLUniversity Hospital Ulm · DEBrigham and Women's Hospital · USGhent University · BEInserm · FRInstituto Português de Oncologia Francisco Gentil · PTInternational Hereditary Cancer Center · PL
Funding
SWOG Foreign AccrualsU10CA037429 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI BLANKE, CHARLES D., MEYSKENS, FRANK L. · 1985 to 2014
$205.2MSWOG NCORP Research BaseUG1CA189974 · NCI · THE HOPE FOUNDATION · PI CHARLES D. BLANKE, DAWN HERSHMAN · 2014 to 2026
$80.6MUNC-CH CENTER FOR ENVIRONMENTAL HEALTH &SUSCEPTIBILITYP30ES010126 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Stephanie Engel · 2001 to 2026
$36.3MAlpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) StudyZIACP010195 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI ALBANES, DEMETRIUS · 2009 to 2025
$22.5MEpidemiological and Clinical Translational Studies Post Genome-Wide AssociationU19CA148537 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI EASTON, DOUGLAS FREDERICK, EELES, ROSALIND · 2010 to 2014
$10.4MPCPT and SELECT cohorts: Core Infrastructure Support for Cancer Research UM1CA182883 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI TANGEN, CATHERINE M., THOMPSON, IAN M. · 2013 to 2017
$5.2MImputation-based approach to identify low frequency variants in prostate cancerU01CA188392 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI SCHUMACHER, FREDRICK RAY · 2014 to 2016
$1.9MRisk Prediction for Development of Adverse Effects FOllowing Radiotherapy for Prostate CancerK07CA187546 · NCI · UNIVERSITY OF ROCHESTER · PI KERNS, SARAH L. · 2015 to 2019
$649kAggressive Prostate Cancer: Linking Epigenomics and Genetics for PreventionK05CA175147 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI STANFORD, JANET L · 2014 to 2018
$445kCancer Research UK 10118Cancer Research UK 10119Cancer Research UK 14136Cancer Research UK 16491Cancer Research UK 16563Cancer Research UK 17528Cancer Research UK 18504Cancer Research UK 19170Medical Research Council G0401527Medical Research Council G1000143Medical Research Council MR/N003284/1NCI NIH HHS K05 CA175147NCI NIH HHS K07 CA187546NCI NIH HHS U01 CA188392NCI NIH HHS U10 CA037429NCI NIH HHS U19 CA148537NCI NIH HHS UG1 CA189974NCI NIH HHS UM1 CA182883NHLBI NIH HHS HHSN268201200008CNHLBI NIH HHS HHSN268201200008INIEHS NIH HHS P30 ES010126
Abstract
Chromosome 8q24 is a susceptibility locus for multiple cancers, including prostate cancer. Here we combine genetic data across the 8q24 susceptibility region from 71,535 prostate cancer cases and 52,935 controls of European ancestry to define the overall contribution of germline variation at 8q24 to prostate cancer risk. We identify 12 independent risk signals for prostate cancer (p < 4.28 × 10
Indexed as
Genetic Predisposition to DiseaseCase-Control StudiesChromosome MappingChromosomes, Human, Pair 8Disease SusceptibilityGenetic MarkersGenotypeHaplotypesHumansMaleProstatic NeoplasmsRisk AssessmentRisk FactorsWhite PeopleGenetic Markers
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT01221168ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.